Tafasitamab is a humanized FC-modified monoclonal antibody that binds to CD19, which is broadly expressed on the surface of B cells. Tafasitamab is indicated for the treatment of B cell malignancies, such as non-Hodgkin's lymphoma (NHL), including diffuse large B cell lymphoma (DLBCL), indolent lymphomas like follicular lymphoma (FL) and marginal zone lymphomas (MZL), as well as chronic lymphocytic leukemia (CLL).